

# Carlo Buonerba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3260462/publications.pdf>

Version: 2024-02-01

158  
papers

3,989  
citations

109321

35  
h-index

149698

56  
g-index

159  
all docs

159  
docs citations

159  
times ranked

5393  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. <i>Urologia Internationalis</i> , 2022, 106, 75-82.	1.3	4
2	COVID-19 and prostate cancer: a complex scenario with multiple facets. <i>Future Science OA</i> , 2022, 8, FSO.	1.9	3
3	Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy. <i>Future Science OA</i> , 2022, 8, FSO784.	1.9	2
4	Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	12
5	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103198.	4.4	35
6	Narrative review of Mediterranean diet in Cilento: longevity and potential prevention for prostate cancer. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110264.	2.0	4
7	Population-based human biomonitoring in the "Land of Fires" Area: innovations in study design and procedures. <i>Future Science OA</i> , 2021, 7, FSO646.	1.9	2
8	The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department. <i>Future Science OA</i> , 2021, 7, FSO635.	1.9	4
9	Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study. <i>Future Science OA</i> , 2021, 7, FSO643.	1.9	20
10	Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 237.	2.5	58
11	Urologic malignancies: advances in the analysis and interpretation of clinical findings. <i>Future Science OA</i> , 2021, 7, FSO674.	1.9	24
12	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. <i>Cancers</i> , 2021, 13, 2359.	3.7	6
13	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 651745.	2.8	11
14	Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study. <i>Future Science OA</i> , 2021, 7, FSO745.	1.9	7
15	The use of <sup>68</sup> Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities. <i>Future Science OA</i> , 2021, 7, FSO705.	1.9	5
16	A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. <i>Future Oncology</i> , 2021, 17, 3987-3994.	2.4	3
17	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6930.	2.5	4
18	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. <i>Future Science OA</i> , 2021, 7, FSO709.	1.9	40

#	ARTICLE	IF	CITATIONS
19	Development of a municipality index of environmental pressure in Campania, Italy. <i>Future Science OA</i> , 2021, 7, FSO720.	1.9	5
20	Immune checkpoint inhibitors in penile cancer. <i>Future Science OA</i> , 2021, 7, FSO714.	1.9	2
21	Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer. <i>Future Science OA</i> , 2021, 7, FSO719.	1.9	6
22	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. <i>Minerva Urology and Nephrology</i> , 2021, 73, 442-451.	2.5	23
23	Assessment of Total, PTEN <sup>+</sup> , and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e286-e298.	1.9	18
24	Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature. <i>Nutrients</i> , 2021, 13, 3750.	4.1	39
25	Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?. <i>Future Science OA</i> , 2021, 7, FSO770.	1.9	4
26	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	3
27	Toll-like receptors and COVID-19: a two-faced story with an exciting ending. <i>Future Science OA</i> , 2020, 6, FSO605.	1.9	96
28	Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020, 10, 1556.	2.8	4
29	Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review. <i>Cancers</i> , 2020, 12, 3634.	3.7	10
30	Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy. <i>Oncology</i> , 2020, 98, 743-747.	1.9	33
31	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 459-464.	1.6	42
32	<p>Management of Ewing Sarcoma Family of Tumors: A Short Description of a Rare Primitive Uterine pPNET and Literature Review</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1179-1184.	2.0	2
33	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 408.	3.7	32
34	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102992.	4.4	28
35	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091.	1.8	7
36	Dysregulated metabolism: a relevant player in prostate cancer progression and clinical management. <i>Translational Andrology and Urology</i> , 2019, 8, S109-S111.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296.	4.4	13
38	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1259.	3.7	18
39	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 377-387.	3.1	43
40	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. <i>Drugs</i> , 2019, 79, 381-400.	10.9	23
41	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1400.	2.8	39
42	Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?. <i>European Urology</i> , 2019, 75, 705-706.	1.9	5
43	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. <i>World Journal of Urology</i> , 2019, 37, 1049-1059.	2.2	5
44	Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 56-62.	0.5	5
45	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018, 4, 874-879.	3.1	30
46	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients. <i>Medicine (United States)</i> , 2018, 97, e11254.	1.0	8
47	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. <i>Journal of Cancer</i> , 2018, 9, 4250-4254.	2.5	26
48	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018, 9, 189.	3.5	26
49	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018, 9, 19861-19873.	1.8	37
50	Serum and tissue markers in colorectal cancer: State of art. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 103-116.	4.4	20
51	Locally advanced paranasal sinus carcinoma: A study of 30 patients. <i>Oncology Letters</i> , 2017, 13, 1338-1342.	1.8	8
52	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Medicine (United States)</i> , 2017, 96, e6817.	1.0	4
53	Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 461.e15-461.e27.	1.6	75
54	Immunotherapy for penile cancer. <i>Future Science OA</i> , 2017, 3, FSO195.	1.9	9

#	ARTICLE	IF	CITATIONS
55	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017, 13, 285-293.	2.4	55
56	The Sooner, the Better: The Establishment of a Treatment Paradigm in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2017, 8, 788.	3.5	2
57	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017, 8, 2663-2668.	2.5	5
58	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. <i>Oncotarget</i> , 2017, 8, 18424-18434.	1.8	52
59	Testicular cancer from diagnosis to epigenetic factors. <i>Oncotarget</i> , 2017, 8, 104654-104663.	1.8	54
60	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16503-e16503.	1.6	0
61	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or 3rd) Line Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 487.	3.5	23
62	Combination therapy for metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2016, 4, 100-100.	1.7	22
63	Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer. <i>Medicine (United States)</i> , 2016, 95, e2598.	1.0	14
64	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. <i>Medicine (United States)</i> , 2016, 95, e2754.	1.0	2
65	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 494-498.	1.9	1
66	Cisplatin- Versus Non-Platinum-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	1.9	12
67	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016, 95, e2598.	1.0	14
68	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1113-1120.	3.1	5
69	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1387-1401.	3.1	22
70	A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e2598.	1.0	14
71	Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 277-279.	2.4	0
72	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016, 12, 399-411.	2.4	39

#	ARTICLE	IF	CITATIONS
73	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016, 69, 634-641.	1.9	53
74	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 386-386.	1.6	0
75	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. <i>Medicine (United States)</i> , 2015, 94, e1861.	1.0	43
76	The evolving landscape in advanced penile cancer. <i>Future Science OA</i> , 2015, 1, FSO9.	1.9	3
77	Third-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Medicine (United States)</i> , 2015, 94, e2297.	1.0	16
78	Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. <i>OncoTargets and Therapy</i> , 2015, 8, 1345.	2.0	6
79	How can we improve prognostic models in renal cell carcinoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1281-1283.	1.8	3
80	The epidermal growth factor receptors as biological targets in penile cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 473-476.	3.1	23
81	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e2117.	1.0	45
82	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 534-541.	4.4	35
83	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015, 26, 236-239.	1.4	7
84	The role of immunotherapy in oncology. <i>Future Oncology</i> , 2015, 11, 2861-2864.	2.4	0
85	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015, 11, 3091-3098.	2.4	17
86	The use of interferon in melanoma patients: A systematic review. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 203-212.	7.2	52
87	Correlative Imaging in a Patient with Cystic Thymoma: CT, MR and PET/CT Comparison. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2015, 80, 22-26.	1.0	9
88	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2015, 10, e0139696.	2.5	39
89	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 335-335.	1.6	0
90	Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program.. <i>Journal of Clinical Oncology</i> , 2015, 33, 225-225.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014, 10, 1353-1360.	2.4	23
92	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. <i>Future Oncology</i> , 2014, 10, 2141-2147.	2.4	30
93	Isin vitro-acquired resistance to enzalutamide a useful model?. <i>Future Oncology</i> , 2014, 10, 2551-2553.	2.4	1
94	Sequential therapies in castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 153-155.	2.4	1
95	Metastasis to the Kidney From a B2 Thymoma. <i>International Journal of Surgical Pathology</i> , 2014, 22, 656-658.	0.8	1
96	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S81-S87.	1.1	104
97	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S65-S72.	1.1	352
98	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S73-S80.	1.1	155
99	Poor Survival in Prostate Cancer Patients with Primary Refractoriness to Docetaxel. <i>European Urology</i> , 2014, 65, 505-507.	1.9	20
100	Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7528-7528.	1.6	4
101	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014, 2, 228.	0.8	18
102	Optimal management of a patient with recurrent nasopharyngeal carcinoma. <i>World Journal of Clinical Cases</i> , 2014, 2, 297.	0.8	8
103	A case series of low-dose sorafenib plus tamoxifen in sorafenib-pretreated patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15139-e15139.	1.6	0
104	Re: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy. <i>European Urology</i> , 2013, 63, 961.	1.9	5
105	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013, 11, 161.	4.4	36
106	Hypercastration in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 303-305.	2.4	1
107	Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 149-151.	3.1	16
108	<b>EGFR mutational status in penile cancer</b>. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 501-505.	3.4	14

#	ARTICLE	IF	CITATIONS
109	Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 761-765.	1.6	16
110	Tumor-to-tumor metastasis. <i>Anti-Cancer Drugs</i> , 2013, 24, 759-764.	1.4	5
111	Comment on: EGFR mutational status in Brazilian patients with penile carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 857-859.	3.4	2
112	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013, 9, 889-897.	2.4	38
113	Penile cancer: current therapy and future directions. <i>Annals of Oncology</i> , 2013, 24, 1179-1189.	1.2	73
114	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013, 24, 84-89.	1.4	29
115	Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas. <i>World Journal of Clinical Oncology</i> , 2013, 4, 47.	2.3	11
116	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml. <i>PLoS ONE</i> , 2013, 8, e67687.	2.5	87
117	Non-AIDS-related Kaposi's sarcoma: A single-institution experience. <i>World Journal of Clinical Oncology</i> , 2013, 4, 52.	2.3	8
118	Long lasting response to second-line everolimus in kidney cancer. <i>World Journal of Clinical Cases</i> , 2013, 1, 166.	0.8	0
119	Capecitabine-gemcitabine in thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18536-e18536.	1.6	0
120	Thymic epithelial tumors at University Federico II of Naples: A 30-year experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7603-7603.	1.6	0
121	Induction docetaxel-cisplatin followed by extended-field radiotherapy in patients with cervical metastases from unknown primary carcinoma. <i>Anticancer Research</i> , 2013, 33, 1135-9.	1.1	5
122	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. <i>Oncology Reports</i> , 2012, 27, 409-15.	2.6	17
123	Non-small cell lung cancer: from targeted therapy to tailored therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1817-1819.	1.8	2
124	Second-line treatment for renal cell cancer. <i>British Journal of Cancer</i> , 2012, 106, 617-618.	6.4	4
125	How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 331-333.	2.4	1
126	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1079-1080.	1.8	2



#	ARTICLE	IF	CITATIONS
127	Combination of docetaxel and cetuximab for penile cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 573-577.	1.4	29
128	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2012, 13, 1676-1686.	2.1	34
129	Cisplatin and 5-Fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012, 110, E661-6.	2.5	76
130	Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. <i>Clinica Chimica Acta</i> , 2012, 413, 1274-1278.	1.1	51
131	Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E99-104.	2.5	48
132	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 309-315.	2.3	44
133	Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. <i>World Journal of Clinical Oncology</i> , 2012, 3, 111.	2.3	14
134	Immunotherapy for the treatment of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 551-561.	27.6	86
135	Neuroendocrine Tumors Diagnosed at the "Antonio Cardarelli" Hospital (Naples, Campania, Italy) between 2006-2009: A Single-Institution Analysis. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 251-256.	2.1	2
136	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011, 107, 234-239.	2.5	82
137	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 54-68.	4.4	79
138	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. <i>European Urology</i> , 2011, 59, 526-540.	1.9	119
139	Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study. <i>European Urology</i> , 2011, 60, 1280-1284.	1.9	73
140	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1455-1461.	2.3	24
141	Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 25-28.	2.4	31
142	Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. <i>World Journal of Clinical Oncology</i> , 2011, 2, 150.	2.3	86
143	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1491-1497.	1.8	23
144	Efficacy of Sunitinib Rechallenge in Kidney Cancer: Are mTOR Inhibitors Involved or Is It Only a Matter of Time?. <i>Onkologie</i> , 2011, 34, 295-296.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. <i>Oncology Letters</i> , 2011, 2, 861-864.	1.8	5
146	Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies. <i>World Journal of Clinical Oncology</i> , 2011, 2, 377.	2.3	36
147	Overall survival is an unsuitable primary end point. <i>Nature Reviews Urology</i> , 2010, 7, 367-368.	3.8	10
148	Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. <i>Anti-Cancer Drugs</i> , 2010, 21, 465-468.	1.4	4
149	Is Hypogammaglobulinemia a Constant Feature in Good's Syndrome?. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1275-1279.	2.1	14
150	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010, 100, 311-319.	2.9	4
151	Docetaxel Rechallenge in Castration-Resistant Prostate Cancer: Scientific Legitimacy of Common Clinical Practice. <i>European Urology</i> , 2010, 58, 636-637.	1.9	26
152	Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 906-911.	1.9	55
153	Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2010, 8, 8.	1.9	3
154	A Long-Lasting Response to Sorafenib Treatment in an Advanced Hepatocellular Carcinoma Patient. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 951-954.	2.1	4
155	The Clinical Impact of a Cardiologic Follow-up in Breast Cancer Survivors: An Observational Study. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1221-1227.	2.1	8
156	Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2010, 70, 983-1000.	10.9	98
157	The therapy of kidney cancer with biomolecular drugs. <i>Cancer Treatment Reviews</i> , 2010, 36, S16-S20.	7.7	33
158	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 2526.	3.3	27